MedTrace Logo

DAPROCA Pelvic Lymph Node Irradiation to Prostate for High Risk Prostate Cancer: Phase I/II Study

NCT01417676 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 87

Last updated 2020-07-01

No results posted yet for this study

Summary

This is a prospective, open label 1 arm study, multicentre, Phase I/II clinical safety study. The trial is designed to gain initial safety and efficacy data on pelvic lymph node radiation with simultaneous integrated boost to prostate in high risk prostate cancer patients.

Conditions

Interventions

RADIATION

Radiation: pelvic lymph nodes with boost to prostate

78(74)Gy/39(37) fractions to prostate, 56(55)GY /39(37) fractions to pelvic lymph nodes, 5 fractions per week.

Sponsors & Collaborators

  • Rigshospitalet, Denmark

    collaborator OTHER

  • Herlev Hospital

    collaborator OTHER

  • Odense University Hospital

    collaborator OTHER

  • Vejle Hospital

    collaborator OTHER

  • Aalborg University Hospital

    collaborator OTHER

  • Danish Center for Interventional Research in Radiation Oncology (CIRRO)

    collaborator OTHER

  • University of Aarhus

    lead OTHER

Principal Investigators

  • Lise N Bentzen, MD., Ph.D · Aarhus University Hospital, Daproca, CIRRO

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-04-30
Primary Completion
2019-05-31
Completion
2019-05-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01417676 on ClinicalTrials.gov